This is why Astrazeneca does not test the Covid vaccine in Italy
The Astrazeneca anti Covid-19 vaccine is not tested in Italy because there is a low viral load from Sars-Cov-2, according to Di Lorenzo (Irbm). On the other hand, the choice of the Italian company Reithera is different
Astrazeneca, which has a phase 2-3 trial of the Covid vaccine developed with the University of Oxford and with the Italian Irbm, has no plans to test the drug in Italy.
Different choice than that made by the Italian company Reithera ,
All the details.
WHERE THE ASTRAZENECA AND IRBM VACCINE TESTS
Where is the Astrazeneca vaccine tested? Volunteers who test the vaccine are scattered across Great Britain (10 thousand), the United States (25 thousand) and Brazil (15 thousand), explained to Repubblica Piero Di Lorenzo of Irbm, a molecular biotechnology company born in Pomezia in 2009.
FUTURE EXPERIMENTATIONS
The vaccine will also be tested in "Japan and Russia", added Di Lorenzo, speaking at Coffee Break, La7 program led by Andrea Pancani .
ITALY: LOW VIRAL CHARGE TO TEST
Among the countries mentioned (present and future), there is not Italy, where Irbm is based, which has collaborated in the creation of the vaccine with the University of Oxford and with Astrazeneca.
The choice is always explained by Di Lorenzo at Coffee Break : "The vaccine is not tested in Italy because now in Italy there is a low Sars-Cov-2 viral load".
THE DIFFERENT CHOICE OF REITHERA
The trials of the vaccine of Reithera, a company based in Castel Romano, started at the end of August. The drug, developed by the company based in Italy and the Spallanzani institute, financed by the Lazio Region (5 million) and the Ministry of Research (3 million), will be tested on 90 Italian volunteers, as reported by Corriere della Sera .
The second phase, the one that should involve 2000-5000 volunteers could also “take place in Italy as soon as the results of the first phase are available. For the third, we are thinking of countries with a high incidence of cases, out of 10 thousand people. The choice will depend on the evolution of the epidemic in the autumn ”, said Antonella Folgori, CEO of Reithera ( here the in-depth analysis by Start Magazine on the company's shareholders, activities, accounts and lenders ).
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/innovazione/ecco-perche-astrazeneca-non-testa-il-vaccino-anti-covid-in-italia/ on Mon, 14 Sep 2020 14:20:41 +0000.